ArticleProceedings of the National Academy of Sciences of the United States of America2018
FcαRI binding at the IgA1 C
Article in Proceedings of the National Academy of Sciences of the United States of America, 2018. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 17 papers.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
17 citing papers in PubMed, 24 citations in OpenAlex.
- Article
- Engineering of anticancer human immunoglobulin A equipped with albumin for enhanced plasma half-life.PNAS nexus · 2025Article
- The role of antibody glycosylation in autoimmune and alloimmune kidney diseases.Nature reviews. Nephrology · 2024Review
- Effects ofFrontiers in molecular biosciences · 2024Article
- Variable-heavy (VH) families influencing IgA1&2 engagement to the antigen, FcαRI and superantigen proteins G, A, and L.Scientific reports · 2022Article
- Advances in IgA glycosylation and its correlation with diseases.Frontiers in chemistry · 2022Review
- Factors underlying asymmetric pore dynamics of disaggregase and microtubule-severing AAA+ machines.Biophysical journal · 2021Article
- Immunoglobulin A Glycosylation and Its Role in Disease.Experientia supplementum (2012) · 2021Article
- Fc Engineering Strategies to Advance IgA Antibodies as Therapeutic Agents.Antibodies (Basel, Switzerland) · 2020Review
- Mechanism and inhibition of Streptococcus pneumoniae IgA1 protease.Nature communications · 2020Article
- Rapid desensitization of humanized mice with anti-human FcεRIα monoclonal antibodies.The Journal of allergy and clinical immunology · 2020Article
- IgA and FcαRI: Versatile Players in Homeostasis, Infection, and Autoimmunity.ImmunoTargets and therapy · 2020Review
- IgA: Structure, Function, and Developability.Antibodies (Basel, Switzerland) · 2019Review
- Distinct Fcα receptorThe Journal of biological chemistry · 2019Article
- Potent Fc Receptor Signaling by IgA Leads to Superior Killing of Cancer Cells by Neutrophils Compared to IgG.Frontiers in immunology · 2019Article
- IgA and FcαRI: Pathological Roles and Therapeutic Opportunities.Frontiers in immunology · 2019Review
- Engineering a pure and stable heterodimeric IgA for the development of multispecific therapeutics.mAbsArticle
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
6 authors at 4 institutions in 1 country.
Funding
Abstract
IgA effector functions include proinflammatory immune responses triggered upon clustering of the IgA-specific receptor, FcαRI, by IgA immune complexes. FcαRI binds to the IgA1-Fc domain (Fcα) at the C
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.